Skip to main content
. 2022 Sep 26;18(9):e1010189. doi: 10.1371/journal.pgen.1010189

Fig 3. Impact of PTGIR agonist/antagonist on CP genes expression in THP-1: parental, PTGIR expressed or knocked-down.

Fig 3

Relative mRNA expression levels of S100A8/A9 genes were evaluated following the treatment of THP-1 parental cell line (A) with 10−5 M PTGIR agonist (Beraprost) or (D) with 10−5 M PTGIR antagonist (Ro 1138452) for 24 h. Relative in mRNA expression levels of S100A8/A9 genes were evaluated in THP-1 cell lines transduced with (B, E) PTGIR ORF or (C, F) PTGIR shRNA following a treatment with either DMSO and either 10−5 M PTGIR agonist (Beraprost) or 10−5 M antagonist (Ro 1138452) for 24 h. Each bar is the mean of 3 samples from 3 different infections ±SEM. *P < .05, ***P < .001 (Student’s t-test unpaired). A dose and time-course response of S100A8/A9 RNA expression to PTGIR agonist Beraprost were performed in parental THP-1 cells (S12 and S13 Figs, respectively); A dose response of S100A8/A9 RNA expression to PTGIR antagonist Ro 1138452 was performed in THP-1 cells transduced with the PTGIR ORF (S14 Fig).